A dose-finding study of the effects of OC000459 on responses to allergen challenge in the Vienna chamber in subjects known to suffer from grass pollen induced allergic rhinitis: a randomised, double-blind placebo-controlled, parallel group evaluation of the dose response curve and minimum effective dose given orally for eight days
Phase of Trial: Phase II
Latest Information Update: 02 Dec 2016
At a glance
- Drugs OC 459 (Primary)
- Indications Allergic rhinitis
- Focus Therapeutic Use
- Sponsors Oxagen
- 26 Nov 2008 Status changed from recruiting to completed, as reported in ClinicalTrials.gov record.
- 11 Jul 2008 New trial record.